Grants for For profit organizations other than small businesses - Science and Technology

This funding opportunity provides financial support for institutions and organizations to create and manage a resource that supplies human tissues and organs for biomedical research, benefiting studies on various diseases and health conditions.

This funding opportunity is designed to support public-private partnerships that leverage artificial intelligence to improve the resilience and competitiveness of U.S. manufacturing through innovative research and workforce development.

The Roanoke County Economic Development Authority’s Business Equipment Acquisition Program (BEAP) Grant is designed to support eligible for-profit businesses within Roanoke County by providing funding for the acquisition of new capital. This program aligns with the Authority's mission to foster economic growth and strengthen local businesses by enabling them to bolster their operations. The grant directly addresses the need for capital investment, which is crucial for business expansion and modernization. The primary target beneficiaries of the BEAP Grant are for-profit businesses located in Roanoke County that meet specific eligibility criteria. To qualify, businesses must employ more than three full-time employees at a physical location in the county, have operated for at least one year, hold a current County or town business license, and be in good standing with all local ordinances and tax requirements. The program's impact goal is to stimulate economic activity by encouraging businesses to invest in new equipment, thereby enhancing productivity, creating jobs, and contributing to the overall economic vitality of Roanoke County. The program prioritizes the acquisition of new capital that falls under taxable business personal property or business machinery and tools, as defined by the Roanoke County Code. Examples of eligible acquisitions include tangible personal property such as furniture, fixtures, office and business machines, tools, and equipment used in various professions. Computer equipment (excluding software) and machinery and tools used in manufacturing, mining, processing, broadcasting, dry cleaners, commercial laundry, and dairy businesses are also specifically eligible. This focus ensures that funding supports tangible assets that directly contribute to operational improvements and business growth. The expected outcomes of the BEAP Grant include increased capital investment by local businesses, enhanced operational capabilities, and ultimately, job retention and creation within Roanoke County. Measurable results will be tied to the number of grants awarded, the total value of capital acquisitions facilitated, and the subsequent economic impact, such as growth in business personal property tax rolls. By providing financial incentives, the program aims to accelerate the modernization and expansion of local enterprises, reinforcing the Authority's strategic priority of nurturing a robust and competitive business environment through direct support and strategic investment.

The SCIRP CTRA is intended to support high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary. Projects should demonstrate potential to impact the standard of care, both immediate and long term, or contribute to evidence-based guidelines for the evaluation and care of military Service Members, Veterans, and other individuals living with SCI. The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to the fiscal year 2024 (FY24) Spinal Cord Injury Research Program (SCIRP) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC) is the program management agent for this funding opportunity. Congress initiated the SCIRP in 2009 to provide support for traumatic spinal cord injury (SCI)-related research of exceptional scientific merit that has the potential to make a significant impact on improving the health and well-being of military Service Members, Veterans, and other individuals living with SCI. Appropriations for the SCIRP from FY09 through FY23 totaled $437.85 million (M). The FY24 Defense Appropriations Act provides $40M to the SCIRP through the appropriation for peer-reviewed spinal cord research. The vision of the SCIRP is to advance the treatment and management of SCI and ameliorate its consequences. The FY24 SCIRP challenges the scientific community to design research that will advance the development or translation of health care solutions for people living with SCI. Innovative research that fosters new directions or addresses neglected issues in the field of traumatic SCI is also supported, although studies focused exclusively on target identification are discouraged. The SCIRP encourages impactful research across the continuum of care from time of injury and across the life span that is well reasoned and scientifically supported. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and/or care partners.

This grant provides funding for technology demonstrations of non-lithium long-duration energy storage solutions, targeting state energy offices, Indian Tribes, educational institutions, electric utilities, and private energy storage companies to advance these technologies towards commercial viability.

This project will increase the capacity of countries to develop effective regulations preventing the proliferation and misuse of commercial spyware in alignment with international best practices and advocate for commercial spyware regulatory approaches that are technically sound and rights-respecting.

This funding opportunity supports collaborative research teams focused on innovative solutions to improve treatments and outcomes for patients with glioblastoma, particularly the IDH-wild type variant.

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

The IDEA Fund program is a state-sponsored venture capital initiative that utilizes public funding (both state and federal) to drive economic development within the state. The primary focus of this program is to foster innovation and support technology-driven entrepreneurial endeavors that contribute to the state’s overall economic development growth. MTC’s Venture Capital Program was created to accelerate private venture capital investment in Missouri-based start-up companies and to increase the overall investment impact of third-party investments. The Venture Capital Program supports technology startups through matching equity or convertible debt investments up to $2,000,000 for the purpose of scaling the business to attract additional venture capital. Since 2010, MTC has invested over $49 million in more than 150 early-stage Missouri-based high-growth technology-focused companies. Since 2018, our portfolio companies have gone on to raise over $1.6 billion in additional private capital.

This funding opportunity provides financial support to Sacramento-based nonprofit cultural organizations and for-profit creative businesses to develop workforce training and internship programs for underserved youth and young adults aged 16-24.

The Program supports research on the sources, sinks, transport, and transformation of gases and aerosols in the atmosphere through models, observations, and experiments, including homogeneous and heterogeneous chemical reactions, emissions, deposition, atmospheric oxidation and photochemistry, aqueous-phase chemistry and aerosol processes; the formation of new particles and secondary organic aerosols, the modeling of atmospheric chemical processes, the study of chemical mechanisms in the atmosphere, optical properties of gases and aerosols, and improved methods for measuring the concentrations of trace species and their fluxes into and out of the atmosphere.The Program encourages principal investigators from a wide variety of institutions and backgrounds to submit proposals.

Main Street Ventures offers Launch Funding to emerging, pre-revenue businesses that have a prototype or product. This grant program aims to support the growth and scaling of businesses within the Greater Cincinnati region, aligning with the foundation's mission to foster economic development and innovation in the area. The funding is specifically designed to cover key direct costs associated with growth projects, rather than general operating expenses, reflecting a strategic priority to provide tangible support for business acceleration. The primary target beneficiaries are business entities (C-Corp, S-Corp, or LLC) with a Federal Tax ID (EIN) located in the Greater Cincinnati region, which includes specific counties in Ohio, Kentucky, and Indiana. Businesses must demonstrate customer demand and strong progression since their founding. The program focuses on specific growth projects that will accelerate business growth, with examples of suitable direct expenses including key equipment, packaging support, and technology product development. This targeted approach ensures that the grant funds directly contribute to measurable business expansion. Special consideration is given to women and minority-owned businesses, as well as businesses that can show matching funds from other sources. This reflects the foundation's strategic priorities to promote inclusivity and leverage additional investment, thereby maximizing the overall impact on the regional economy. The expected outcomes include the scaling of businesses, job creation, and increased economic vitality within the Greater Cincinnati region, with successful applicants demonstrating a clear impact of the grant funds on their business or the region. The Main Street Ventures' theory of change is rooted in providing early-stage, direct financial assistance to promising businesses to help them overcome critical growth hurdles. By focusing on direct costs and specific growth projects, the program aims to create a ripple effect, enabling these businesses to achieve significant milestones that would otherwise be out of reach. The emphasis on local businesses and underrepresented founders further amplifies the foundation's commitment to building a robust and equitable entrepreneurial ecosystem in the Greater Cincinnati area. The grant duration of three years allows for sustained support and monitoring of the businesses' progress.

This funding opportunity supports innovative research on rare cancers, providing up to $490,000 for early-stage projects that aim to improve diagnosis, understanding, and treatment, particularly benefiting military service members, veterans, and the general public.

The Women's Philanthropy Society is offering grants to support a legacy of love and an enduring gift for future generations, addressing a broad spectrum of issues that impact community quality of life. For 2024, the Society has chosen Health & Wellness as its focus issue. This grant program aims to strategically address this focus area, align with the Society's philanthropic mission, and contribute to systemic change in the community. The target beneficiaries are organizations described in Code Section 170(c)(2), 501(c)(3), 2055(a)(2) or 2522(a)(2), excluding private foundations. This also includes schools, religious institutions, or government agencies located in the Greater Huntsville area. The grants are intended to create a positive impact on the health and wellness of the community, with a specific focus on the Greater Huntsville, Alabama geographic area, including Jackson, Limestone, Madison, Marshall, and/or Morgan counties. Priority will be given to projects that strategically address the Health & Wellness focus area, involve more than one agency or organization and are collaborative in nature, address a desired systemic change, and provide clear and measurable outcomes. The funding information indicates that up to two high-impact $50,000 grants may be awarded, with the overall grant size ranging from $10,000 to $100,000. Expected outcomes include measurable improvements in health and wellness within the Greater Huntsville area, facilitated by collaborative efforts and systemic changes. The Society's strategic priorities are evident in its emphasis on projects with clear and measurable outcomes and a collaborative approach. The theory of change appears to be that by strategically funding projects that address systemic issues in health and wellness through collaborative efforts, the Women's Philanthropy Society can create a lasting positive impact on the quality of life in the community.

This funding opportunity provides financial support to organizations that create pathways to success for young people aged 12 to 24, particularly those from marginalized communities in King County, Washington, by focusing on education, workforce development, and mentorship.

The Arizona Department of Veterans' Services (ADVS) provides critical, statewide coordination and technical assistance to services and organizations serving Veterans. This includes activities such as the Arizona Veteran StandDown Alliance, and outreach events that support homeless and at-risk military Veterans in Cochise, Coconino, Gila, Graham/Greenlee, La Paz, Maricopa, Mohave, Navajo, Pima, Pinal, Yavapai, and Yuma Counties. Financial Notes: Total Funding for this grant is $303,000

This funding opportunity is designed for U.S.-based research institutions to advance the measurement of exoplanet masses, enhancing our understanding of their characteristics and formation processes.

The OCRP seeks to advance ovarian cancer research through development of early-career investigators. The OCRP Ovarian Cancer Academy (OCA) is a unique, interactive environment providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty to move ovarian cancer research into a new frontier. The overarching goal of the OCA is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment to enhance quality and expand quantity of the ovarian cancer research field.

This grant provides funding to U.S.-based organizations, including universities and companies, to develop innovative technologies that enhance plant engineering for sustainable energy and bioenergy production.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.